Date stringdate 2012-01-01 00:00:00 2023-12-31 00:00:00 | Stock_symbol stringlengths 1 5 | Article_title stringlengths 1 255 | Article stringlengths 1 342k |
|---|---|---|---|
2022-03-09 00:00:00+00:00 | ABBV | Genmab (GMAB), AbbVie Lymphoma Candidate Gets Orphan Drug Tag | Denmark-based biotech Genmab A/S GMAB received Orphan Drug designation for its antibody product candidate, epcoritamab, for treating follicular lymphoma (“FL”) from the FDA.
The orphan drug designation is granted by the FDA to a drug or biologic intended to treat a rare disease or condition, which generally includes a ... |
2022-03-09 00:00:00+00:00 | ABBV | Health Care Sector Update for 03/09/2022: AMYT, PFE, ABBV, IBB, XLV | Health care stocks were climbing premarket Wednesday. The iShares Biotechnology ETF (IBB) and the Health Care SPDR (XLV) were recently up around 2%.
Amryt Pharma (AMYT) reported Q4 net earnings of $0.07 per diluted share, compared with a loss of $0.28 per share a year earlier. Three analysts polled by Capital IQ expect... |
2022-03-09 00:00:00+00:00 | ABBV | What's in Store for These 3 Big Pharma Outperformers in 2022? | The recently ended fourth-quarter earnings season was a mixed bag for the drug and biotech sector. Most companies beat estimates for earnings while missing the same for sales or vice versa. However, some companies have not only been able to beat consensus estimates but also guide better than market expectations for 202... |
2022-03-09 00:00:00+00:00 | ABBV | 8 Strong Uptrend Stocks to Buy on the Next Dip | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Given the remarkable volatility we’ve seen this year, it’s a wonder there are any uptrend stocks left to find. As the saying goes, though, “There’s always a bull market somewhere.” It’s an observation that holds even in volatile 2022.
U.S. stocks topped ou... |
2022-03-08 00:00:00+00:00 | ABBV | AbbVie Resolves All U.S. HUMIRA Litigation With Alvotech | (RTTNews) - AbbVie (ABBV) said that it has resolved all U.S. HUMIRA (adalimumab) litigation with Alvotech.
As per the terms of the resolution, AbbVie will grant Alvotech a non-exclusive license to its HUMIRA-related patents in the United States, which will begin on July 1, 2023.
AbbVie will make no payments of any form... |
2022-03-08 00:00:00+00:00 | ABBV | AbbVie (ABBV) Outperforms Industry This Year So Far: What Next? | AbbVie ABBV stock has risen 11.6% this year so far compared with a decrease of 3.1% for the industry.
Image Source: Zacks Investment Research
AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal has transformed Abb... |
2022-03-08 00:00:00+00:00 | ABBV | Top Analyst Reports for Microsoft, Amazon & NVIDIA | Tuesday, March 8, 2022
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Amazon.com, Inc. (AMZN) and NVIDIA Corporation (NVDA). These research reports have been hand-picked fro... |
2022-03-07 00:00:00+00:00 | ABBV | What's Next For Merck Stock After A 6% Fall In A Month? | The stock price of Merck (NYSE: MRK) has seen a fall of 6% over the last month, while it is down 1% year-to-date. This marks a better performance than the broader markets, with the S&P500 down 6% over the last month but down 10% so far this year. The decline in broader markets can be attributed to the geopolitical tens... |
2022-03-06 00:00:00+00:00 | ABBV | You Could Make $48,840 in Annual Income by Buying These 10 Stocks | Let first give you the cold, hard truth. It takes money to make money. You're not going to magically receive a significant income each year without having a hefty amount of cash to invest.
But the good news is that many Americans who have consistently saved and invested throughout their careers can retire with $1 milli... |
2022-03-05 00:00:00+00:00 | ABBV | 4 Defensive Stocks To Watch As Russia-Ukraine War Intensifies | Do You Have These Defensive Stocks On Your March 2022 Watchlist?
Among the main concerns on investors’ minds now would be the ongoing war in Ukraine and upcoming interest rate hikes. With these two daunting factors to consider moving forward, defensive stocks could be in focus in the stock market now. Overall, markets ... |
2022-03-05 00:00:00+00:00 | ABBV | 1 Healthcare Stock That Could Fly Higher After a Strong Q4 | The pharmaceutical business can be challenging for companies and investors as money is poured into developing drugs that may or may not achieve U.S. Food and Drug Administration (FDA) or international approval to market and sell.
Innoviva (NASDAQ: INVA) approaches investing in pharmaceuticals differently. It doesn't ma... |
2022-03-04 00:00:00+00:00 | ABBV | AbbVie (ABBV) Up 6.9% Since Last Earnings Report: Can It Continue? | It has been about a month since the last earnings report for AbbVie (ABBV). Shares have added about 6.9% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is AbbVie due for a pullback? Before we dive into how investors and analysts have re... |
2022-03-04 00:00:00+00:00 | ABBV | 1 Stock Warren Buffett Is Selling That Income Investors Should Consider Buying | Warren Buffett appears to be selling more stocks than he's buying these days. Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) recently revealed its equity holdings for the fourth quarter of 2021 in a regulatory filing. Buffett and his investment managers sold 10 stocks while buying seven stocks.
The legendary investor u... |
2022-03-03 00:00:00+00:00 | ABBV | Is This Dividend King a Buy for 2022 and Beyond? | High inflation rates, looming interest rate hikes, and most recently Russia's invasion of Ukraine have all led to a return of market volatility in 2022. For context, the S&P 500 has fallen 9% year to date.
One company that has nevertheless managed to do well lately is pharma stock AbbVie (NYSE: ABBV), whose shares are ... |
2022-03-03 00:00:00+00:00 | ABBV | Viatris Just Snagged a Major FDA Approval | In early February, the U.S. Food and Drug Administration (FDA) gave the nod to Viatris' (NASDAQ: VTRS) Restasis, a generic version of AbbVie's (NYSE: ABBV) dry eye disease eyedrop treatment.
Since Viatris launched the drug in the U.S. immediately after the FDA approval, let's dig into what it could mean for patients an... |
2022-03-02 00:00:00+00:00 | ABBV | 2 Fantastic Dividend Stocks for Retirees | Many retirees face the challenge of how to bring in regular income beyond their Social Security benefits. One way to make sure the bill are paid (or in some cases, the beach house mortgage is covered) is to invest in companies that pay dividends.
AbbVie (NYSE: ABBV) and Kimberly-Clark (NYSE: KMB) are two income stocks ... |
2022-03-02 00:00:00+00:00 | ABBV | Consumer Spending, E-Commerce, and the Business of Lodging | In this week's episode of Motley Fool Money, Motley Fool analyst Olivia Zitkus and Motley Fool contributor Keith Speights, along with host Chris Hill, discuss a new wave of biosimilar drugs and the challenges (and opportunities for investors) that they present. Also, Motley Fool analyst Bill Mann discusses:
Retail sale... |
2022-03-02 00:00:00+00:00 | ABBV | Harpoon Therapeutics: HPN217 Receives FDA Fast Track Designation | (RTTNews) - Harpoon Therapeutics, Inc. (HARP) said FDA has granted Fast Track designation to HPN217, a BCMA-targeting TriTAC, for the treatment of patients with relapsed, refractory multiple myeloma who have received at least four lines of therapy.
Julie Eastland, President and CEO, Harpoon Therapeutics, said: "We are ... |
2022-03-02 00:00:00+00:00 | ABBV | Has the Market Correction Made AbbVie Stock Cheap? | With the stock market down about 8% so far this year -- and briefly entering correction territory last week -- investors are on the lookout for shares of quality companies that have dropped into bargain territory. AbbVie's (NYSE: ABBV) stock, however, has been moving up rather than down so far in 2022. Is it a buy?
Bef... |
2022-03-01 00:00:00+00:00 | ABBV | U.S. lawmakers seek answers on 'troubling' drug price increases | By Diane Bartz
WASHINGTON, March 1 (Reuters) - Senators Elizabeth Warren and Amy Klobuchar and 11 other U.S. lawmakers pressed the president of the biggest pharmaceutical industry trade group Tuesday about what they said were "troubling price increases for brand name drugs" in January.
A letter to Stephen Ubl, presiden... |
2022-03-01 00:00:00+00:00 | ABBV | Warren, 12 other U.S. lawmakers press drugs lobby group on price increases | By Diane Bartz
WASHINGTON, March 1 (Reuters) - Senators Elizabeth Warren and Amy Klobuchar and 11 other U.S. lawmakers pressed the president of the biggest pharmaceutical industry trade group on Tuesday about what they said were "troubling price increases for brand name drugs" in January.
A letter to Stephen Ubl, presi... |
2022-02-28 00:00:00+00:00 | ABBV | Reata's (RETA) Q4 Earnings Miss Mark, Revenues Decline Y/Y | Reata Pharmaceuticals, Inc. RETA reported fourth-quarter 2021 loss of $2.35 per share, wider than the Zacks Consensus Estimate of a loss of $2.31.
However, the above loss included stock-based compensation and a non-cash interest expense. Adjusted loss for the quarter was $1.59 per share, also wider than the loss of $1.... |
2022-02-28 00:00:00+00:00 | ABBV | The 2 Best ETFs for Dividends | During a market like we have experienced over the past few months when the major benchmarks are posting negative year-to-date returns, dividend income becomes even more important for many investors. That extra income can either be reinvested back in stocks or an exchange-traded fund, at a cheaper price if the investmen... |
2022-02-27 00:00:00+00:00 | ABBV | Investing in Pharma Stocks? Avoid Doing These 3 Things | Pharmaceutical stocks can be great tools for building wealth, provided that you understand how and why to use them -- and how not to. Like all investments, it's entirely possible to get burned by pharma stocks, so you'll want to minimize the risks.
To help you on your journey, here are three of the biggest mistakes tha... |
2022-02-27 00:00:00+00:00 | ABBV | If You Invested $25,000 in AbbVie In 2013, This Is How Much You Would Have Today | AbbVie (NYSE: ABBV) is one of the top healthcare companies in the world, with a market cap of $256 billion. That's a higher valuation than Abbott Laboratories' $209 billion which AbbVie spun off from in 2013.
The stock has been a major performer for shareholders. But just how much would you have made if you'd invested ... |
2022-02-27 00:00:00+00:00 | ABBV | These 5 Stocks Will Make Me More Than $3,000 in Passive Income This Year | Easy money. It might seem like an elusive dream. However, investors actually have plenty of opportunities to make money without expending a lot of effort.
Dividend stocks especially stand out as an easy way to generate recurring income. And you don't have to give up on opportunities for growth with some dividend stocks... |
2022-02-26 00:00:00+00:00 | ABBV | 3 Pharma Stocks That Retired Investors Should Love | I loathe broccoli. But my family loves it. Different people have different preferences when it comes to food. It's a similar story with investing. Some stocks that appeal to younger investors won't appeal to retired investors -- and vice versa.
We asked three Motley Fool contributors to weigh in on pharmaceutical stock... |
2022-02-25 00:00:00+00:00 | ABBV | Noteworthy Friday Option Activity: MMM, CI, ABBV | Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in 3M Co (Symbol: MMM), where a total volume of 30,918 contracts has been traded thus far today, a contract volume which is representative of approximately 3.1 million underlying shares (given that every 1 cont... |
2022-02-24 00:00:00+00:00 | ABBV | ABBV: Phase 3 Study Confirms Upadacitinib Improved Clinical & Endoscopic Outcomes In Crohn's Disease | (RTTNews) - AbbVie (ABBV) said that the second phase 3 induction study confirmed Upadacitinib (RINVOQ) improved clinical and endoscopic outcomes in patients with moderate to severe Crohn's disease.
In U-EXCEL, the second of two Phase 3 induction studies, a significantly higher proportion of patients with moderate to se... |
2022-02-23 00:00:00+00:00 | ABBV | 7 High-Yield Blue-Chip Stocks Suitable for Any Retiree | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Investors seeking safety, value, and income are running out of choices. The mounting volatility in the stock market is hurting the stock’s safety. Stock markets are assessing January’s 7.5% consumer price index. This is raising volatility and creating the i... |
2022-02-23 00:00:00+00:00 | ABBV | MGV, BRK.B, JNJ, ABBV: Large Inflows Detected at ETF | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Mega Cap Value ETF (Symbol: MGV) where we have detected an approximate $165.6 million dollar inflow -- that's a 3.4% increase week over week in outstanding units (from 46,760,539 to... |
2022-02-22 00:00:00+00:00 | ABBV | Want to Get Richer? 5 Best Stocks to Buy Now and Hold Forever | Creating wealth in the stock market can be as simple as owning pieces of the world's most powerful corporations and letting them compound for decades. But you can't pick just any stock; most won't cut it over the long-term.
Sometimes if it's broken, don't fix it. Some companies have been compounding for decades, and ar... |
2022-02-22 00:00:00+00:00 | ABBV | Viatris (VTRS) to Report Q4 Earnings: What's in the Cards? | Viatris VTRS, a global healthcare company, is scheduled to report fourth-quarter 2021 results on Feb 28.
The company was formed in 2020 through the combination of Mylan and Upjohn. It beat earnings estimates in each of the trailing four quarters, the average surprise being 14.3%. In the last reported quarter, the compa... |
2022-02-21 00:00:00+00:00 | ABBV | AbbVie Is a Top Pick in an Uncertain Market | A host of macroeconomic issues have rattled the stock market and the economy so far in 2022. Major U.S. indices are down for the year. Some, like the Nasdaq, are down more than 10% year to date amid volatile trading.
AbbVie (NYSE: ABBV), on the other hand, has been on a tear, gaining over 20% in the last six months, an... |
2022-02-21 00:00:00+00:00 | ABBV | Here's How Much You Can Retire With by Investing Just $2,827 Every Year | The average refund for the 2020 tax year was $2,827. While many people treat those refunds as windfalls to be spent on splurges such as vacations or large purchases, paying down debt -- particularly high-interest rate debt -- is a better option. But if you don't have any high-interest rate debt (and you do have suffici... |
2022-02-20 00:00:00+00:00 | ABBV | Investing $20,000 in These 5 Stocks Could Give You $6,000 in Annual Income | Make your money work for you. That's good advice for any investor. But it's great advice for income-seeking investors.
Dividend stocks provide an excellent way to put your money to work -- especially with certain stocks. Investing $20,000 in each of these five stocks could give you roughly $6,000 in annual income.
Imag... |
2022-02-19 00:00:00+00:00 | ABBV | This Number Is a Big Green Flag for AbbVie Stock | Investors might be numb to the common reminder that "past performance is no guarantee of future returns," but that doesn't stop companies like AbbVie (NYSE: ABBV) from working hard to replicate their prior successes. With the end of patent exclusivity looming for its rock star drug, Humira, the pharma juggernaut is scr... |
2022-02-18 00:00:00+00:00 | ABBV | 7 Value Stocks to Buy in This Pricey Market | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Value stocks are always in fashion. But after nearly 18 months where investors could find growth in usual and unusual places, value stocks got crowded out. This time, they said, was different.
It wasn’t and it isn’t. If the recent market selloff has taught ... |
2022-02-18 00:00:00+00:00 | ABBV | Ironwood (IRWD) Q4 Earnings Miss, Linzess Volume Grows | Ironwood Pharmaceuticals, Inc. IRWD reported fourth-quarter 2021 adjusted earnings of 27 cents per share, missing the Zacks Consensus Estimate of 31 cents. The company had reported adjusted earnings of 36 cents per share in the year-ago quarter.
Total revenues of $117.1 million beat the Zacks Consensus Estimate of $109... |
2022-02-18 00:00:00+00:00 | ABBV | Zacks Value Trader Highlights: Mastercard, Visa, Chevron and AbbVie | For Immediate Release
Chicago, IL – February 18, 2022 – Zacks Value Trader is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here:... |
2022-02-18 00:00:00+00:00 | ABBV | AbbVie Snags FDA Approval for Another Indication. Will It Become Another Blockbuster? | AbbVie (NYSE: ABBV) has taken an important step toward replacing the revenue decline that will result from Humira's patent protection expiration in the U.S. next year.
That step is approval from the U.S. Food and Drug Administration (FDA) to use AbbVie's Skyrizi to treat patients with active psoriatic arthritis, a dise... |
2022-02-17 00:00:00+00:00 | ABBV | Daily Dividend Report: HUM,CSCO,WCN,SWK,ABBV | Humana announced today that its Board of Directors has declared a cash dividend to stockholders of $0.7875 per share payable on April 29, 2022 to stockholders of record as of the close of business on March 31, 2022. The dividend of $0.7875 per share reflects an increase of 12.5 percent from the previous per share divid... |
2022-02-16 00:00:00+00:00 | ABBV | Abbvie Inc Shares Climb 0.3% Past Previous 52-Week High - Market Mover | Abbvie Inc (ABBV) shares closed 0.3% higher than its previous 52 week high, giving the company a market cap of $255B. The stock is currently up 8.0% year-to-date, up 45.1% over the past 12 months, and up 195.6% over the past five years. This week, the Dow Jones Industrial Average fell 1.2%, and the S&P 500 fell 1.1%.
T... |
2022-02-16 00:00:00+00:00 | ABBV | 2 Warren Buffett Stocks to Buy and Hold Forever | Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.
Buffett oversees his company's inve... |
2022-02-16 00:00:00+00:00 | ABBV | Why Abbvie Might Be Poised for a Return to Profitability | In this clip from "The Pharma & Biotech Show" on Motley Fool Live, recorded on Feb. 2, Motley Fool contributors Keith Speights and Brian Orelli assess the pharma giant's projection that it'll return to growth quickly in the second half of the decade.
{% sfr %}
Keith Speights: Here's the statement that really jumped ou... |
2022-02-16 00:00:00+00:00 | ABBV | Amgen Snags Another Approval for This Promising Cancer Drug | Late last month, Japan's Ministry of Health, Labour and Welfare (MHLW) approved Amgen's (NASDAQ: AMGN) Lumakras to treat advanced non-small cell lung cancer (NSCLC) adult patients with the KRAS G12C mutation that worsened after prior therapy.
The MHLW gave Lumakras the nod just days after the European Commission approv... |
2022-02-15 00:00:00+00:00 | ABBV | Biohaven (BHVN) Migraine Drug Meets Study Goals in China | Biohaven Pharmaceutical Holding Company Ltd. BHVN, along with partner Pfizer Inc. PFE, announced positive top-line data from a phase III study evaluating the safety and efficacy of the orally dissolving tablet (“ODT”) formulation of rimegepant for the acute treatment of migraine in China and South Korea.
The study met ... |
2022-02-15 00:00:00+00:00 | ABBV | Abbvie Inc Shares Climb 0.2% Past Previous 52-Week High - Market Mover | Abbvie Inc (ABBV) shares closed 0.2% higher than its previous 52 week high, giving the company a market cap of $252B. The stock is currently up 6.7% year-to-date, up 43.3% over the past 12 months, and up 195.9% over the past five years. This week, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 1.8%.
T... |
2022-02-15 00:00:00+00:00 | ABBV | XLV, ABBV, TMO, MRK: Large Inflows Detected at ETF | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR— Fund (Symbol: XLV) where we have detected an approximate $341.6 million dollar inflow -- that's a 1.0% increase week over week in outstanding units (from ... |
2022-02-14 00:00:00+00:00 | ABBV | 4 Top Stock Trades for Tuesday: SE, ABBV, TD, CAR | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Stocks were hit overnight, finding their footing near the open but coming under more selling pressure thanks to the escalating geopolitical tensions in Eastern Europe. Here are a few top stock trades to focus on going into the week.
Top Stock Trades for Tom... |
2022-02-14 00:00:00+00:00 | ABBV | 7 Dividend Aristocrats That Could Outpace This Volatile Market | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Dividend aristocrats are companies that have raised their dividend payments at least once a year for the past 25 years. Many of these names move on to become dividend kings that have increased payouts for 50 consecutive years. Investors who want sustainable... |
2022-02-14 00:00:00+00:00 | ABBV | Got $1,000? 5 Buffett Stocks to Buy and Hold Forever | Warren Buffett's investing savvy through his holding company Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) has made more millionaires than almost every other company in history. For instance, a $1,000 investment made in the stock when Buffett stepped in as CEO in 1965 would now be worth $18 million.
Though Buffett's in... |
2022-02-14 00:00:00+00:00 | ABBV | Zacks Industry Outlook Highlights: Sanofi, AbbVie, Bristol-Myers, Amgen and Vertex Pharmaceuticals | For Immediate Release
Chicago, IL – February 14, 2022 – Today, Zacks Equity Research discusses Sanofi SNY, AbbVie ABBV, Bristol-Myers BMY, Amgen AMGN and Vertex Pharmaceuticals VRTX.
Industry: Big Pharma
Link: https://www.zacks.com/stock/news/1866486/will-the-rally-of-these-5-big-drugmakers-continue-in-2022
The broader... |
2022-02-14 00:00:00+00:00 | ABBV | Buffett's Berkshire bought Activision Blizzard before deal | Adds Daniel Loeb purchase
Feb 14 (Reuters) - Warren Buffett's Berkshire Hathaway Inc BRKa.Nloaded up on shares in video game maker Activision Blizzard Inc ATVI.O ahead of Microsoft Corp's MSFT.O $68.7 billion deal to buy the company, according to a regulatory filing.
Microsoft announced its acquisition of "Call of Duty... |
2022-02-14 00:00:00+00:00 | ABBV | Buffett's Berkshire buys Activision Blizzard, cuts healthcare positions | By David Randall
Feb 14 (Reuters) - Warren Buffett's Berkshire Hathaway Inc BRKa.N said on Monday it added nearly 14.7 million shares of video game maker Activision Blizzard Inc ATVI.O ahead of Microsoft Corp's MSFT.O $68.7 billion deal to buy the company.
The company also added to its position in energy giant Chevron ... |
2022-02-12 00:00:00+00:00 | ABBV | Is the FDA's Partial Hold Bad News for Gilead Investors? | With Gilead Sciences' (NASDAQ: GILD) drug magrolimab now under a partial clinical hold with the U.S. Food and Drug Administration, how big of a setback could it be for the company? In this segment from "This Week in Healthcare," recorded on Jan. 31, Motley Fool contributors Brian Orelli and Keith Speights discuss what'... |
2022-02-11 00:00:00+00:00 | ABBV | 2 Dividend Stocks That Are Better Investments Than AT&T | Investors in AT&T (NYSE: T) are likely down on the news that they will be collecting less in dividends from the telecom giant. An adjustment, however, wasn't a surprise given that the company was spinning off WarnerMedia and hinted last year that it would need to "resize" its dividend.
However, there are arguably bette... |
2022-02-11 00:00:00+00:00 | ABBV | Will the Rally of These 5 Big Drugmakers Continue in 2022? | The broader market index, S&P 500, has been declining since the beginning of 2022 as economy reel under the pressure of uncertainty related to macro factors, including interest rate hike, supply chain constraints and higher inflation.
The uncertainty around the macro factors has hurt the majority of medical sector indi... |
2022-02-11 00:00:00+00:00 | ABBV | 2 Green Flags For Gilead Sciences' Future | Biotech giant Gilead Sciences (NASDAQ: GILD) has encountered its share of headwinds in the past two years. For instance, in late 2020 the company lost patent exclusivity in the U.S. for Truvada and Atripla -- both of which are HIV treatments -- leading to lower sales for both drugs.
Also, the drugmaker's much-anticipat... |
2022-02-10 00:00:00+00:00 | ABBV | Notable Thursday Option Activity: DRI, GM, ABBV | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Darden Restaurants, Inc. (Symbol: DRI), where a total of 5,161 contracts have traded so far, representing approximately 516,100 underlying shares. That amounts to about 45.2% of DRI's average daily trading volume ove... |
2022-02-10 00:00:00+00:00 | ABBV | The Zacks Analyst Blog Highlights AbbVie, The Boeing Company, Infosys Limited, Ford Motor Company and Public Storage | For Immediate Release
Chicago, IL – February 10, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie Inc. ABBV, The Boe... |
2022-02-10 00:00:00+00:00 | ABBV | Interesting ABBV Put And Call Options For April 14th | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the April 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new April 14th contracts and identified one put and one call contract of particular interest.
The put contract... |
2022-02-09 00:00:00+00:00 | ABBV | Abbvie Inc Shares Approach 52-Week High - Market Mover | Abbvie Inc (ABBV) shares closed today at 0.3% below its 52 week high of $143.60, giving the company a market cap of $253B. The stock is currently up 7.1% year-to-date, up 40.6% over the past 12 months, and up 198.5% over the past five years. This week, the Dow Jones Industrial Average rose 0.2%, and the S&P 500 fell 0.... |
2022-02-09 00:00:00+00:00 | ABBV | Amgen (AMGN) Provides Strong Long-Term Outlook, Shares Up | Amgen AMGN announced an attractive outlook for the company’s business through the end of this decade. Amgen estimates its revenues to increase by mid-single-digit percentage points every year till 2030. The adjusted earnings are expected to exhibit a compound annual growth rate in the range of high single-digit to low ... |
2022-02-08 00:00:00+00:00 | ABBV | 3 Top Healthcare Stocks to Buy for February | According to Verified Market Research, the global healthcare industry is worth $3.3 trillion today and could grow to $6.6 trillion by 2028. So you might want to consider having healthcare stocks in your portfolio, especially if you're a long-term investor.
The good news is that these companies come in all sorts of flav... |
2022-02-08 00:00:00+00:00 | ABBV | Allergan Aesthetics: FDA Approves JUVÉDERM VOLBELLA XC For Improvement Of Infraorbital Hollows | (RTTNews) - Allergan Aesthetics, an AbbVie company (ABBV), announced the FDA approval of JUVÉDERM VOLBELLA XC for improvement of infraorbital hollows in adults over the age of 21. JUVÉDERM VOLBELLA XC was first approved in 2016 for use in the lips and perioral rhytids. The latest approval marks the sixth approved indic... |
2022-02-07 00:00:00+00:00 | ABBV | Notable ETF Inflow Detected - IWF, ADBE, ABBV, AVGO | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 Growth ETF (Symbol: IWF) where we have detected an approximate $317.5 million dollar inflow -- that's a 0.5% increase week over week in outstanding units (from 254,450,0... |
2022-02-07 00:00:00+00:00 | ABBV | These 2 Mega-Cap Stalwart Stocks Just Hit All-Time Highs | The stock market had another up-and-down day on Monday, as investors tried to get used to volatile conditions. Important questions like whether inflation will prove to be fleeting or how much the Federal Reserve might act to boost interest rates won't get answers in the immediate term. But market participants are still... |
2022-02-07 00:00:00+00:00 | ABBV | Abbvie Inc Shares Near 52-Week High - Market Mover | Abbvie Inc (ABBV) shares closed today at 0.2% below its 52 week high of $142.80, giving the company a market cap of $248B. The stock is currently up 5.0% year-to-date, up 35.4% over the past 12 months, and up 191.9% over the past five years. This week, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 1.... |
2022-02-07 00:00:00+00:00 | ABBV | Does AbbVie (NYSE:ABBV) Have A Healthy Balance Sheet? | The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it might be obvious that you need to consider debt, when you think about how ris... |
2022-02-07 00:00:00+00:00 | ABBV | The Zacks Analyst Blog Highlights: AbbVie, Merck, Eli Lilly, Novartis and Pfizer | For Immediate Release
Chicago, IL – February 7, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie ABBV, Merck MRK, El... |
2022-02-05 00:00:00+00:00 | ABBV | Could This New Indication Create a Blockbuster for Pfizer? | In mid-January, Pfizer (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) gave the nod to Cibinqo as a treatment for patients with moderate to severe atopic dermatitis (eczema) whose disease wasn't adequately controlled with other treatments.
Why did the FDA approve Cibinqo for moderate to severe ec... |
2022-02-05 00:00:00+00:00 | ABBV | Is AbbVie Stock a Buy Now? | Drugmaker AbbVie (NYSE: ABBV) has historically been a safe, market-beating stock to own. Over the past five years, its total returns (which include dividend income) of 191% have eclipsed the S&P 500, which has increased by 113% when factoring in its distributions.
But there have been question marks about the future of ... |
2022-02-04 00:00:00+00:00 | ABBV | Abbvie Inc Shares Approach 52-Week High - Market Mover | Abbvie Inc (ABBV) shares closed today at 0.7% below its 52 week high of $141.71, giving the company a market cap of $248B. The stock is currently up 5.0% year-to-date, up 37.7% over the past 12 months, and up 192.0% over the past five years. This week, the Dow Jones Industrial Average rose 2.8%, and the S&P 500 rose 3.... |
2022-02-04 00:00:00+00:00 | ABBV | Viatris (VTRS) Gets FDA Nod for Generic Drug in Dry Eye Disease | Viatris VTRS announced that the FDA has approved the abbreviated new drug application filed by Mylan Pharmaceuticals, a subsidiary of Viatris, which sought approval for a generic version of Restasis (cyclosporine ophthalmic emulsion 0.05%).
We note that Restasis was initially developed by Allergan, an AbbVie ABBV compa... |
2022-02-04 00:00:00+00:00 | ABBV | Pharma Stock Roundup: MRK, LLY, ABBV Post Q4 Earnings, PFE Ends Vupanorsen Program | This week, AbbVie ABBV, Merck MRK, Eli Lilly LLY and Novartis NVS announced fourth-quarter and full-year 2021 results. Pfizer PFE stopped clinical development of vupanorsen, which was being evaluated in cardiovascular risk reduction and severe hypertriglyceridemia indications and returned development rights to partner ... |
2022-02-03 00:00:00+00:00 | ABBV | AbbVie (ABBV) Q4 2021 Earnings Call Transcript | Image source: The Motley Fool.
AbbVie (NYSE: ABBV)
Q4 2021 Earnings Call
Feb 02, 2022, 9:00 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good morning and thank you for standing by. Welcome to the AbbVie fourth quarter 2021earnings conference call [Operator instr... |
2022-02-02 00:00:00+00:00 | ABBV | 5 Top Stock Trades for Thursday: AMD, NVDA, FB, QCOM, ABBV | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
We’re in the thick of earnings season, with more big reports due up after the close and again on Thursday. With that in mind, let’s look at a few top stock trades going into the back-half of the week.
Top Stock Trades for Tomorrow No. 1: Advanced Micro Devi... |
2022-02-02 00:00:00+00:00 | ABBV | AbbVie Q4 21 Earnings Conference Call At 9:00 AM ET | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on February 2, 2022, to discuss Q4 21 earnings results.
To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events
The views and opinions expressed herein are the views and opinions of the author and do ... |
2022-02-02 00:00:00+00:00 | ABBV | U.S. FDA approves first generic form of AbbVie's eye drug | Adds background, details on drug
Feb 2 (Reuters) - The U.S. Food and Drug Administration said on Wednesday it had approved the first generic version of AbbVie's ABBV.N drug, Restasis, to increase tear production in patients with dry eye syndrome.
The condition, which affects millions of Americans every year, occurs whe... |
2022-02-02 00:00:00+00:00 | ABBV | Noteworthy Wednesday Option Activity: ABBV, ORCL, QRVO | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 39,971 contracts have traded so far, representing approximately 4.0 million underlying shares. That amounts to about 47.3% of ABBV's average daily trading volume over the p... |
2022-02-02 00:00:00+00:00 | ABBV | Abbvie Inc Shares Climb 0.2% Past Previous 52-Week High - Market Mover | Abbvie Inc (ABBV) shares closed 0.2% higher than its previous 52 week high, giving the company a market cap of $242B. The stock is currently up 2.2% year-to-date, up 40.2% over the past 12 months, and up 183.2% over the past five years. This week, the Dow Jones Industrial Average rose 3.2%, and the S&P 500 rose 4.3%.
T... |
2022-02-02 00:00:00+00:00 | ABBV | AbbVie (ABBV) Tops Q4 Earnings Estimates | AbbVie (ABBV) came out with quarterly earnings of $3.31 per share, beating the Zacks Consensus Estimate of $3.29 per share. This compares to earnings of $2.92 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 0.61%. A quarter ago, it was e... |
2022-02-02 00:00:00+00:00 | ABBV | AbbVie's (ABBV) Q4 Earnings Surpass Estimates, Sales Miss | AbbVie Inc. ABBV reported earnings of $3.31 per share for the fourth quarter of 2021, beating the Zacks Consensus Estimate of $3.29 and exceeding the guided range of $3.24 to $3.28 per share. Earnings rose 13.4% year over year.
The company’s revenues of $14.89 billion slightly missed the Zacks Consensus Estimate of $15... |
2022-02-02 00:00:00+00:00 | ABBV | AbbVie Guides FY22 Adj. EPS Above Estimates - Quick Facts | (RTTNews) - While reporting financial results for the fourth quarter on Wednesday, biopharmaceutical company AbbVie Inc. (ABBV) initiated its earnings and adjusted earnings guidance for the full-year 2022.
For fiscal 2022, AbbVie now projects earnings in a range of $9.26 to $9.46 per share and adjusted earnings in a ra... |
2022-02-02 00:00:00+00:00 | ABBV | AbbVie forecasts 2022 profit above estimates on strong sales of Botox, Skyrizi | Feb 2 (Reuters) - AbbVie Inc ABBV.N forecast full-year adjusted profit above estimates on Wednesday, as its blockbuster anti-wrinkle injection Botox and newer psoriasis drug Skyrizi beat Wall Street expectations for quarterly sales.
The company's best-selling drug Humira is expected to face competition from rivals in t... |
2022-02-02 00:00:00+00:00 | ABBV | AbbVie Q4 Profit Increases, beats estimates | (RTTNews) - AbbVie (ABBV) released earnings for its fourth quarter that increased from last year and beat the Street estimates.
The company's bottom line came in at $4.04 billion, or $2.26 per share. This compares with $36 million, or $0.01 per share, in last year's fourth quarter.
Excluding items, AbbVie reported adju... |
2022-02-01 00:00:00+00:00 | ABBV | Why AbbVie (ABBV) Might Surprise This Earnings Season | Investors are always looking for stocks that are poised to beat at earnings season and AbbVie Inc. ABBV may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because AbbVie is seeing favorable earnings estimate revision activity as of lat... |
2022-02-01 00:00:00+00:00 | ABBV | AbbVie a Top Socially Responsible Dividend Stock With 4.1% Yield (ABBV) | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 4.1% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of... |
2022-02-01 00:00:00+00:00 | ABBV | Gilead COVID drug takes top spot for U.S. hospital spending -report | By Deena Beasley
Feb 1 (Reuters) - Gilead Sciences Inc's GILD.O COVID-19 drug remdesivir last year overtook AbbVie Inc's ABBV.N 20-year-old arthritis drug Humira as the medicine that U.S. hospitals spent the most on, according to Vizient Inc, a purchasing group used by about half the nation's hospitals.
Remdesivir, an ... |
2022-02-01 00:00:00+00:00 | ABBV | Pharma Stocks to Report Q4 Earnings on Feb 2: ABBV, NVS & NVO | The pharma bellwether, Johnson & Johnson JNJ, marked the beginning of earnings season for pharma/drug/biotech companies from the Medical sector when it reported its fourth-quarter results on Jan 25, 2022. This was followed by fourth-quarter results of large-cap biotech, Vertex Pharmaceuticals, and generic drugmaker, Dr... |
2022-02-01 00:00:00+00:00 | ABBV | Pre-Market Earnings Report for February 2, 2022 : ABBV, TMO, WM, BSX, EMR, JCI, HUM, ROP, MPC, IDXX, RACE, ODFL | The following companies are expected to report earnings prior to market open on 02/02/2022. Visit our Earnings Calendar for a full list of expected earnings releases.
AbbVie Inc. (ABBV)is reporting for the quarter ending December 31, 2021. The large cap pharmaceutical company's consensus earnings per share forecast fr... |
2022-02-01 00:00:00+00:00 | ABBV | 5 High-Yield Dividend Stocks That Can Save Your Portfolio During a Stock Market Crash | January provided a not-so-subtle reminder that stock market crashes and corrections are a normal part of the investing cycle, and they can occur without warning. Both the benchmark S&P 500 and growth stock-driven Nasdaq Composite endured their steepest corrections in close to two years.
While steep moves lower in the m... |
2022-02-01 00:00:00+00:00 | ABBV | 3 Warren Buffett Dividend Stocks to Buy in February | Warren Buffett has given Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) shareholders a lot through the years. Most importantly, under his direction, Berkshire has handily beaten the market.
However, there's one thing that Oracle of Omaha hasn't given Berkshire shareholders -- a dividend. That doesn't mean that Buffett ... |
2022-02-01 00:00:00+00:00 | ABBV | 3 Pharmaceutical Stocks With Dividend Yields of 2.9% or Better | Nervous investors have been selling risky growth stocks in favor of profit-generating businesses that pay steady dividends. The pharmaceutical industry is one area of the stock market that dividend-seeking investors haven't rushed into yet which means some reliably profitable big pharma companies are offering above-ave... |
2022-02-01 00:00:00+00:00 | ABBV | Abbvie Inc Shares Approach 52-Week High - Market Mover | Abbvie Inc (ABBV) shares closed today at 0.9% below its 52 week high of $138.30, giving the company a market cap of $241B. The stock is currently up 2.1% year-to-date, up 39.8% over the past 12 months, and up 182.0% over the past five years. This week, the Dow Jones Industrial Average rose 2.1%, and the S&P 500 rose 2.... |
2022-01-31 00:00:00+00:00 | ABBV | Bristol-Myers (BMY) to Post Q4 Earnings: What's in Store? | Bristol-Myers Squibb Company BMY is scheduled to report fourth-quarter 2021 results on Feb 4, before market open.
The company’s shares have gained 4.3% in the past year against the industry's decline of 38.8%.
Image Source: Zacks Investment Research
Bristol-Myers has had a pretty decent track record, beating earnings e... |
2022-01-31 00:00:00+00:00 | ABBV | AbbVie's (ABBV) Q4 Earnings May Reflect Slower Sales Recovery | AbbVie, Inc.’s ABBV fourth-quarter results are likely to reflect the impact of the recovering trend in drug sales being observed since the second quarter of 2021. The majority of the company’s drugs, especially the aesthetics franchise, witnessed a strong recovery in the past two quarters. However, in certain disease a... |
2022-01-31 00:00:00+00:00 | ABBV | Zacks Investment Ideas feature highlights: Bank of America, AbbVie, and Microsoft | For Immediate Release
Chicago, IL – January 31, 2022 – Today, Zacks Investment Ideas features: Bank of America BAC, AbbVie ABBV, and Microsoft MSFT.
Value, Growth or Momentum: What Kind of Investor Are You?
The Covid-19 pandemic impacted all of us in many different ways. From work to family to finances, we were forced ... |
2022-01-30 00:00:00+00:00 | ABBV | Better Dividend Stock: AbbVie or Pfizer? | The healthcare sector offers income-seeking investors plenty of attractive stocks to consider. AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) especially stand out. In this Motley Fool Live video recorded on Jan. 19, Motley Fool contributors Keith Speights and Brian Orelli discuss which of these two dividend stocks is the b... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.